The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis
Open accessAbstract
Summary Background A vaccine targeting human papillomavirus (HPV) types 16 and 18, associated with 80% of anal cancers, has demonstrated high efficacy in males. High-risk populations such as men who have sex with men (MSM) may especially benefit from HPV vaccination. To inform immunization guidelines in the U.S., we evaluated the cost-effectiveness of HPV vaccination of MSM. Methods We used decision-analytic models to estimate the direct health and economic outcomes of HPV vaccination in averting HPV-related anal cancer and genital warts, varying age at vaccination, prior exposure to vaccine-targeted HPV types, prevalence of HIV, and other uncertainties. Findings HPV vaccination of MSM at an early age had a cost of $15,290 per quality-adjusted life year (QALY) gained, compared to no vaccination. If MSM are vaccinated at later ages, when exposure to HPV infections is higher, the cost-effectiveness ratios become less attractive but consistently fall below $50,000 per QALY in the majority of evaluated scenarios. Results were most sensitive to rates of anal cancer incidence, duration of vaccine protection, and HIV prevalence among MSM. Interpretation Our analysis suggests that, based on the current evidence, HPV vaccination of MSM is a robustly attractive strategy across a wide range of uncertainties. Funding J Kim is funded in part by grants from the National Cancer Institute (R01 CA93435) and the Bill and Melinda Gates Foundation (30505).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998) · Medical Care · doi:10.1097/00005650-199806000-00002 · Cited by 357
Cited by
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Silverberg, M. J., Lau, B., Justice, A. C., Engels, E., Gill, M. J., Goedert, J. J., Kirk, G. D., D'Souza, G., Bosch, R. J., Brooks, J. T., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1012 · Cited by 520
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study
Giuliano, A. R., Lee, J.-H., Fulp, W., Villa, L. L., Lazcano, E., Papenfuss, M. R., Abrahamsen, M., Salmeron, J., Anic, G. M., Rollison, D. E., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62342-2 · Cited by 500
Hirth, J. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1512453 · Cited by 256
Comprehensive clinical care for men who have sex with men: an integrated approach.
Mayer, K. H., Bekker, L.-G., Stall, R., Grulich, A. E., Colfax, G., & Lama, J. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60835-6 · Cited by 167
Metadata
- Authors
- Kim, J. J.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 10
- Issue
- 12
- Pages
- 845-852
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2138135112
- Cited by
- 182
- References
- 2
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(10)70219-x
- The paper
- Kim, J. J. (2010). Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(10)70219-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.